ArticleCurrent microbiology2025
Development of a Multiplex Real-Time PCR for Diagnosis of Tuberculosis and Multidrug Resistance.
Article in Current microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The aim of this study was to develop a multiplex qPCR method for diagnosis of tuberculosis and multidrug resistance. The method was constructed with two multiplex qPCR mixes. Mycobacterium tuberculosis and rifampicin (RIF) resistance were assessed in the first PCR mix and isoniazid (INH) resistance in the second PCR mix. Firstly, PCR amplification conditions and concentration of primers and probes were optimized. Then, analytical sensitivity/limit of detection (LOD), analytical specificity, repeatability, accuracy, and effectiveness on clinical samples were analyzed. The LOD value was determined as 124 cfu/mL. In studies conducted on 273 clinical samples, RIF and INH resistance was detected with ≥ 99% sensitivity and specificity. No false positive or negative results were obtained in the accuracy studies. In intra-experiment, inter-experiment, and inter-lot repeatability studies, the coefficient of variation was calculated as between 0.36 and 5.3%. It was also determined that the primers/probes used in this assay did not cross-react with microorganisms other than M. tuberculosis complex. In conclusion, the method optimized in the current study has high performance characteristics indicating that it can be used as an alternative for currently available molecular methods for rapid and accurate diagnosis of pulmonary tuberculosis and multidrug resistance without needing any specific equipment. Further study with different clinical samples will be useful to provide more data regarding routine utility of this method.
Indexed as
Identifiers
40153064What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.